All News

RheumNow Podcast square

Early, Aggressive and Seropositive (7.22.2022)

Jack Cush, MD

Dr. Jack Cush covers the news and journal reports from the past week on RheumNow.com. This week we have Insights NAFLD, overdose deaths, septic arthritis, refractory stills, & when MTX doesn’t work.

Read Article
question-mark-1872634_640.jpg

Still’s Disease FAQs

Jack Cush, MD

What is the classic 'triad' of Still's disease? Does it affect males and females equally? What are typical lab findings? Which drugs are effective at treating Still's, and as importantly, which ones are not? What about complications? Read on for these and other FAQs regarding Still's disease.

Read Article
2021,year

ICYMI: 2021 Rheumatology Year in Review

Jack Cush, MD

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
RheumNow Podcast square

Two Week Twitter (6.17.2022)

Jack Cush, MD

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.

Read Article
Biologic.choice.MD_.jpeg (keep)

Not All RA Drug Classes Are Created Equal

MedPage Today

Clear differences were apparent among the three major types of targeted medications for rheumatoid arthritis (RA) in a large European registry study.

Read Article
RheumNow Podcast square

EULAR 2022 Top 10 Abstracts (6.10.2022)

Jack Cush, MD

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the  aid of the RheumNow EULAR faculty.

Read Article
cancer search news magnify

Malignancy risk on b/tsDMARDs in patients with prior malignancy history

Eric Dein, MD

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern.

Read Article
Puzzle pieces

Polymyalgia rheumatica immunological puzzle further illustrated

David Liew, FRACP

Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015) prese

Read Article
Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/QUTIbK3r89 https://t.co/FZcTLREida

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologist Survey: What do you rely on MOST in diagnosing Still’s disease? Sxs? Labs? Both? Criteria? Fever? Vote here: https://t.co/oANKpKqJA5 https://t.co/LIjRSBHNBi

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Stills (or Not) MAS off of Tocilizumab https://t.co/YGEifF5X8K https://t.co/719RjYzbE3

Links:

Dr. John Cush RheumNow ( View Tweet)
#Bestinclass. #Giantcellarteritis GCA lots of novel ideas. V short prednisone- 2 months with #Tocilizumab. Not RCT. Looked safe & effective but too small to know if blindness etc are increased. Don’t suggest you try this at home...yet! @RheumNow @eular_org #EULAR2022 OP0185

Janet Pope Janetbirdope ( View Tweet)

Unizony et al. GCA outcome on/after tocilizumab. 36.5% relapse after stopping tocilizumab. Generally stopped due to remission, 10% stopped due to adverse event @RheumNow #EULAR2022 POS0267 https://t.co/jlZDTinfCK
Richard Conway RichardPAConway ( View Tweet)
Schmitt et al. Pharmacokinetic study of IV tocilizumab in 24 patients with known GCA. Using 6mg/kg or 7mg/kg. Effective on lab measures and no GCA flares. @RheumNow #EULAR2022 POS0268 https://t.co/uhxfGZvYTw
Richard Conway RichardPAConway ( View Tweet)
Tomelleri @tomelleri_a et al. GCA. Tocilizumab weekly x 1 year, then every other week x 1 year, then stop. 2 PMR flares during toc. 1 month post-stop 100% remission. 6 months post-stop 24% GCA flare! Some patients seem to need indefinite toc @RheumNow #EULAR2022 POS0266 https://t.co/8I5GQ08HDr
Richard Conway RichardPAConway ( View Tweet)
Sanchez-Martin et al. Tocilizumab in newly diagnosed vs refractory GCA. 471 patients. Appears of relatively similar efficacy in both groups. Surprising that the difference is not greater given refractory GCA inherently more complex @RheumNow #EULAR2022 POS0817 https://t.co/HEWzYCz9YD
Richard Conway RichardPAConway ( View Tweet)
Preito-Pena at al. Tocilizumab in LVV-GCA and TAK. Similar responses in both, with 75% showing complete clinical response but only 20% complete imaging response at month 12. Clinical implications of these persistent imaging findings need clarification @RheumNow #EULAR2022 POS0804 https://t.co/sNbRzIkwnt
Richard Conway RichardPAConway ( View Tweet)
Unizony et al. Case series of tocilizumab + 8 weeks steroid in GCA. 30 patients, 50% new 50% relapsing. 77% in sustained remission at week 52! No vision loss. Exciting, needs an RCT @RheumNow #EULAR2022 OP0185 https://t.co/ohBYIWYxBC https://t.co/fsn4x17Hwv

Links:

Richard Conway RichardPAConway ( View Tweet)
Sanchez-Bilbao et al. TCZ for large vessel GCA. Has been a concern due to limited LVV/imaging in RCTs 196 patients. Seems to work well. 20% sustained remission month 6, 60% month 12. Clinically significant reduction steroid doses as shown in figure. @RheumNow #EULAR2022 POS0802 https://t.co/Z0HEVal6RI
Richard Conway RichardPAConway ( View Tweet)
TOFFIFE RCT in colchicine-resistant FMF. Tocilizumab normalises SAA and CRP/ESR with PGA response in 20-25%. Maybe response criteria too strict, or maybe TCZ only effective for subgroup of patients @RheumNow #EULAR2022 OP0043 https://t.co/kNs8DMzXFB https://t.co/QMDk1IUkjx

Links:

Richard Conway RichardPAConway ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×